ライフサイエンスコーパス: control test

1 rcise); no exercise was performed before the control test.

2 omalizumab was evaluated using the urticaria control test.

3 thma control was assessed through the Asthma Control Test.

4 uilibrium, haplotype relative risk, and case-control tests.

5 did not behave differently during snake and control tests.

6 CF intervention on the CDI, A-not-B, or self-control tests.

7 stantial power advantages over standard case-control tests.

8 , while adult ALC numbers were comparable to control testes.

9 EGF mutant testes divide faster than GSCs in control testes.

10 d are still regularly detected during import control testing.

11 bacteria that are widely used during quality control testing.

12 xtraction cartridge and subjected to quality control testing.

13 ntly offered psychotherapy in the absence of controlled tests.

14 ory Disorders (14 points), (3) the Sinusitis Control Test (14 points), and (4) the EQ-5D (13 points).

15 n this region and the validity of the Asthma Control Test (ACT) and childhood ACT (C-ACT) in relation

16 thma QOL Questionnaire (miniAQLQ) and Asthma Control Test (ACT) at baseline and 6 months postoperativ

17 Poor asthma control was defined by an Asthma Control Test (ACT) score <20 (n = 287), and dyspnea was

18 d were positively correlated with the asthma control test (ACT) score (r = 0.3678, p = .0035) and neg

19 ercentage of patients who achieved an asthma control test (ACT) score of 20 or greater or an increase

20 oss of smell, and nasal blockage, and Asthma Control Test (ACT) score were collected from hospital re

21 asure of ICS response was a change in Asthma Control Test (ACT) score; the secondary measure was a ch

22 controller inhalers, with suboptimal Asthma Control Test (ACT) scores (ACT score </=19).

23 d an improvement in lung function and Asthma Control Test (ACT) scores in both cohorts.

24 severity of food-allergic reactions, Asthma Control Test (ACT) scores, FA-QoL, and total IgE levels.

25 Change in the Asthma Control Test (ACT) was a primary outcome.

26 d Asthma Control Test (C-ACT) and the Asthma Control Test (ACT), and calculated the minimal important

27 2 (SNOT-22), nasal polyp score (NPS), Asthma Control Test (ACT), and EPOS 2012 CRS clinical control a

28 Pulmonary function tests, Asthma Control Test (ACT), Asthma Health Questionnaire-JAPAN (A

29 a survey which included the NEAT, the Asthma Control Test (ACT), the Asthma Quality of Life Questionn

30 hma control was assessed by using the Asthma Control Test (ACT).

31 Communication Instrument (PACCI), the Asthma Control Test (ACT; or the childhood ACT for children 4-1

32 y asthma control as measured with the Asthma Control Test (ACT; range, 5 [poor] to 25 [complete contr

33 control of asthma in N-ERD patients (asthma control test [ACT]: N-ERD 66.7% less controlled/uncontro

34 ere asthma incidence, asthma control (asthma control test, ACT), lung function (FEV(1)), quality of l

35 ngioedema (AE)-QoL Questionnaire, Angioedema Control Test (AECT), Patient Global Impression of Severi

36 ed us to develop such a tool, the Angioedema Control Test (AECT).

37 ut remembered a similar number of details as controls tested after 1 mo.

38 Asthma control was defined by the Asthma Control Test and annual exacerbation history.

39 control, as measured by the Childhood Asthma Control Test and Asthma Control Test in children and adu

40 roved PAA control (measured using the Asthma Control Test and five-item Asthma Control Questionnaire

41 test ranges that allow for on-scale quality control testing and translation across One Health sector

42 ing a Go-NoGo paradigm, behavioral cognitive control tests and symptom questionnaires.

43 ross-correlation scores from 0.33 to 1.00 in controlled tests and achieving 0.96 correlation in real-

44 associated with worse asthma control (Asthma Control Test) and increased odds of severe as opposed to

45 ry, physical examination, spirometry, asthma control test, and doctor's diagnosis were collected.

46 ife Questionnaire-Marks (AQLQ-M), the Asthma Control Test, and generic measures of QoL developed by t

47 y addressing technical aspects (like version control, testing, and maintenance), community-building s

48 Infection control, testing, and occupational policies to reduce ex

49 study (GWAS) on 2274 dyslexia cases and 6272 controls, testing associations at the single variant, ge

50 IQOLS, other asthma outcome measures (Asthma Control Test, Asthma Symptom Utility Index, and the Mark

51 column) and distilled water (1-phase column/control test) at constant influx rates for a period of t

52 Higher scores on the Asthma Control Test before randomization (indicating better con

53 However, on the working memory control tests, both groups performed similarly.

54 ll-controlled asthma of the Childhood Asthma Control Test (C-ACT) and the Asthma Control Test (ACT),

55 The Childhood Asthma Control Test (C-ACT) is a clinically validated tool.

56 eeism, the number of children with an Asthma Control Test/Childhood Asthma Control Test score of less

57 d in the serum of other inflammatory disease controls tested compared to healthy controls.

58 Control tests confirmed that light aversion was dependen

59 Odor-controlled tests confirmed that turtles were using visua

60 All batches passed quality control testing, confirming suitability for human use.

61 Although asthma control test did not differ between groups (P=.288), pat

62 alk, were compared with the recollections of controls tested directly after the walk (C1), after one

63 ocampal damage remembered fewer details than controls tested directly after the walk but remembered a

64 rly produced ventricular fibrillation in the control tests done 1 week before and after the test, wit

65 ent endotoxin detection platform for quality control testing during therapeutic development.

66 uents in powder and to conduct rapid quality-control tests during GnP production.

67 iants (BA.1 and BA.2) compared with negative controls tested during the same period.

68 quiring rapid, sensitive, and robust quality control tests, e.g., for the quantification of the encap

69 a unified analysis framework for building a controlled test environment where we can jointly model s

70 Controlled test environments were created in a chamber t

71 is more powerful than the corresponding case-control test for detecting digenic interactions in vario

72 ontal lobe lesions and PD while the VMT is a control test for the visuomotor component of the SWT.

73 e efficiency of treatments compared with the control tests for debittering process of table black oli

74 A questionnaire was sent to cases and controls tested from 1-21 February 2021.

75 lowest oxyhaemoglobin saturation during the control test had the greatest quadriceps fatigue attenua

76 ionnaires (Sinonasal Outcome Test-22, Asthma Control Test, Healthy Days Core Module-4, Short Form-36

77 went the psychometric battery and inhibitory control test (ICT) (a test of response inhibition) and d

78 ndard psychometric tests (SPT) or inhibitory control test (ICT) can be used to diagnose MHE.

79 The Inhibitory Control Test (ICT) measures response inhibition and has

80 iagnosis by rapid screening using inhibitory control test (ICT) with treatment; and (5) no MHE diagno

81 Critical Flicker Frequency (CFF), Inhibitory Control Test (ICT), EncephalApp (Stroop), and Continuous

82 red using weighted-lures from the Inhibitory Control Test (ICT).

83 connection [NCT-A and B]) and the inhibitory control test (ICT).

84 encephalopathy score (PHES), and inhibitory control tests (ICTs) were administered to patients with

85 the Childhood Asthma Control Test and Asthma Control Test in children and adults, respectively.

86 ich has several advantages over classic case-control tests, in particular by avoiding recruitment of

87 rming single-marker and haplotype-based case-control tests, including a novel haplotype test based on

88 serial product characterization and quality control tests, including measurements of their fluoresce

89 LS scores and lung function, symptom, Asthma Control Test, Juniper Mini Asthma Quality of Life Questi

90 not different for the MDAT, A-not-B, or self-control tests; mean CDI score was not different in unadj

91 We enrolled cases (testing positive) and controls (testing negative) from among the population wh

92 cases (testing positive for SARS-CoV-2) and controls (testing negative) with molecular SARS-CoV-2 di

93 za viruses by molecular or antigen test, and controls tested negative for influenza viruses and sever

94 ificity of 100% (95% CI 98.9-100; 339 of 339 controls tested negative) and sensitivity of 95.9% (89.8

95 All controls tested negative.

96 irus by real-time polymerase chain reaction; controls tested negative.

97 rse-transcription polymerase chain reaction; controls tested negative.

98 We used a case-control test-negative design to assess the effectiveness

99 Using a case-control test-negative design, a secondary analysis of da

100 0-2011, and 2011-2012 using a case-positive, control test-negative study design.

101 We used a case-control, test-negative design to assess vaccine effectiv

102 Using a case-control, test-negative design, we assessed vaccine effec

103 ip-based system as a new tool in the quality control testing of a recombinant, adenoviral, gene thera

104 sively, early technical development and case-control testing of exhaled breath condensate microRNAs w

105 roved methods for the production and quality control testing of inactivated polio vaccines.

106 nd will be incorporated into routine quality control testing of polysaccharide powders to be used in

107 ected to support the development and quality control testing of protein pharmaceuticals.

108 thinlayer chromatographic method for quality control testing of the purified CBB lots was also develo

109 Many case-control tests of rare variation are implemented in stati

110 Quality control tests of the B. subtilis GeneChip were performed

111 tion was impaired, there were no deficits in control tests of the discrimination of unfamiliar voices

112 ying dimension shared by several visuo-motor control tests of the Nike battery.

113 ecognition, and odor identification, and two control tests of working memory.

114 on of such a protocol involving single-blind controlled testing of 9 CM solutions.

115 Standardized controlled testing of emerging methane detection solutio

116 We built several nanostructures for well-controlled testing of various design rules, and demonstr

117 edral graphene is an ideal platform for well-controlled tests of many-body theory, and reveal magneti

118 th baseline testing on day 1, post-stress or control testing on day 2, and evaluation of long-term st

119 control, measured based on Childhood Asthma Control Test or the Asthma Control Test scores and rescu

120 RM was assessed using a novel computer-controlled test paradigm in which ES to left or right hi

121 logy and culture remain important as quality control tests, particularly in studies of treatment effi

122 Mean changes in symptom scores on the Asthma Control Test (placebo, 1.98 [95% CI, 1.42-2.54] vs soy i

123 assay (EIA) were similar, but 18% of healthy controls tested positive by RT-PCR.

124 We develop a general powerful mdFDR controlling testing procedure and illustrate the methodo

125 e-based)-were evaluated using a single-blind controlled testing protocol at an outdoor facility desig

126 re of Olfactory Disorders, and the Sinusitis Control Test provided the highest quality CRS-specific P

127 conventional physical and mechanical quality control tests provides a complete set of response matric

128 ogue Scale (r = 0.5722, P < 0.01) and asthma control test (r = -0.6483, P < 0.01).

129 tation tests for any situation in which case-control tests require adjustment for confounding covaria

130 +/- 5% (n = 5) and passed all of the quality control tests required by the U.S. Pharmacopeia for radi

131 Based on these laboratory-controlled test results and observations, recommendation

132 - 4.1 and complete response rates (Urticaria Control Test score >= 12) of 92%, 36%, 82%, and 40%, res

133 ut well-controlled asthma (defined as Asthma Control Test score >= 20), controller medication use in

134 = -0.43; P = 0.01) and directly with Asthma Control Test score (beta = 1.09; P = 0.04), while patrol

135 1.44; P = .68; age 6-11 years) or the Asthma Control Test score (DeltaM - DeltaP, 0.51; 95% CI, -0.46

136 re was no difference in the Childhood Asthma Control Test score (difference in change with mometasone

137 oms, episodes of poor asthma control, Asthma Control Test score (range, 5-25; higher scores indicate

138 4 4.1 and complete response rates (Urticaria Control Test score 12) of 92%, 36%, 82%, and 40%, respec

139 The primary outcome was the change in Asthma Control Test score at 6 months.

140 y efficacy end point was change in Urticaria Control Test score at week 22.

141 ntrolled or uncontrolled according to Asthma Control Test score cut-off: 20) and eight healthy contro

142 At 6 months, the difference in Asthma Control Test score improvement was not statistically sig

143 with an Asthma Control Test/Childhood Asthma Control Test score of less than the control threshold of

144 onide: normalization of (1) symptoms (Asthma Control Test score, >19/25 or 50% increase), (2) spirome

145 er prevalence of uncontrolled asthma (Asthma Control Test score, <20) than subjects with singly incre

146 [SD] change from baseline to week 52: Asthma Control Test score, -1.16 [4.14] vs placebo, -2.88 [5.38

147 ant improvements in lung function and Asthma Control Test score, along with a significant decrease in

148 nophil counts and negatively with the Asthma Control Test score, FEV1 (percent predicted), FEV1/force

149 mmunophenotyping that differed by the Asthma Control Test score.

150 pitalizations (beta = 0.24) and worse Asthma Control Test scores (beta = 0.20).

151 Childhood Asthma Control Test or the Asthma Control Test scores and rescue inhaler use.

152 olled or uncontrolled on the basis of asthma control test scores and the number of severe attacks in

153 b demonstrated similar improvement in Asthma Control Test scores compared with intraclass switching.

154 Urticaria Control Test scores increased with lirentelimab across c

155 Urticaria Control Test scores increased with lirentelimab across c

156 asthma, eDNA-high patients had lower Asthma Control Test scores, frequent history of chronic mucus h

157 c parameters were associated based on Asthma Control Test scores, numbers of exacerbations, and visit

158 are visits, or hospitalizations), and Asthma Control Test scores.

159 s in Asthma Control Questionnaire and Asthma Control Test scores.

160 Control tests showed little evidence of gross deficits i

161 Control tests showed that they solved the task using lea

162 In contrast, control test sites outside of the bithorax complex permi

163 RA also underwent symptom assessment (Asthma Control Test), spirometry, exhaled nitric oxide and indu

164 During the first (control) test, subjects exercised at approximately 85% o

165 Multiple samples were taken from subjects in controlled tests such as secondary contact with gunshot

166 rasferase (ChAT)-negative, and preabsorption control tests suggest they may contain chicken-GnRH-II (

167 A series of control tests suggests the effects of the mAChR antagoni

168 nglucosylated substrates that fail a quality control test, supporting additional rounds of chaperone

169 nglucosylated proteins that fail the quality control test, supporting ER retention through persistent

170 blishment of ES cell lines, rigorous quality control testing that included assessment of pluripotency

171 on, lengthy sample preparation, and multiple control tests that need to be performed separately must

172 Quality control testing to assess system and substrate reproduci

173 The Urticaria Control Test (UCT) is a well-established, very easy to u

174 sment and for the key outcome, the urticaria control test (UCT) score, respectively, and patients wit

175 n MC histology, provocation tests, urticaria control test (UCT), and dermatology life quality index (

176 vely assess urticaria control, the Urticaria Control Test (UCT).

177 ety and disease activity (UAS7 and urticaria control test [UCT]).

178 sease control prior to omalizumab (Urticaria Control Test, UCT, 4.0 vs. 6.0, p < 0.001), and lower fa

179 Control tests used for each trial were fermented only by

180 he four filters was predicted to be 41% in a control test using 37 known HIV-1 non-nucleoside reverse

181 Control tests using non-specific myoglobin antigen confi

182 Quality control testing (visual inspection, pH, radiochemical pu

183 Quality control testing was performed on 3 sequential batches of

184 Using a series of control tests we show that inference performance cannot

185 Quality control tests were performed for both scanners.

186 Standard quality control tests were performed on the product according to

187 Quality control tests were performed on the resulting tracer sol

188 quality of life (HRQoL), GINA and the Asthma Control Test, were used for evaluation.

189 The properties of this robust genomic control test with 2 df are examined by simulation.

190 g non-specific binding low as established in control tests with a non-metastatic cancer cell line (He

191 To test for linkage after significant case-control tests, within-family tests are performed.

192 Only 1 of 40 control tests yielded a false-positive result.